NIAID- VRC- Research, Development, and Production to Support Clinical Trials for HIV Vaccines.

NIAID-VRC-支持 HIV 疫苗临床试验的研究、开发和生产。

• 批准号: 10722425
• 负责人: DAVID LINDSAY
• 金额: $ 1014.32万
• 依托单位: LEIDOS BIOMEDICAL RESEARCH, INC.
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-04-12 至 2027-07-17
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10722425
• 关键词: Biological Assay; Clinic; Clinical Trials; Development; HIV vaccine; Health; Human; Laboratories; Mission; National Institute of Allergy and Infectious Disease; Phase; Production; Research; Testing; Toxicology; United States National Institutes of Health; Vaccine Research; Vaccines; human disease; improved; large scale production; manufacturing process; meetings; research and development; vaccine development

The Dale and Betty Bumpers Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), at the National Institutes of Health, was established to facilitate research in vaccine development and is dedicated to improving global human health through the rigorous pursuit of effective vaccines and treatments for human diseases. One of the key components of the VRC's mission involves the rapid advancement of promising candidates from the laboratory to the clinic. Meeting this mission necessitates the development and manufacturing of vaccines for toxicology, and Phase 1/11 clinical trials.

美国国立卫生研究院国家过敏和传染病研究所 (NIAID) 戴尔和贝蒂·邦珀斯疫苗研究中心 (VRC) 的成立是为了促进疫苗开发研究，致力于通过严格追求有效的疫苗和人类疾病治疗方法来改善全球人类健康。 VRC 使命的关键组成部分之一涉及将有前途的候选人从实验室快速推进到临床。完成这一使命需要开发和生产用于毒理学的疫苗以及 1/11 期临床试验。